Advertisement


Christopher A. Barker, MD, on Locally Advanced Unresectable CSCC: RAMPART Trial

ASCO 2026

Advertisement

Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).



Related Videos

Lung Cancer

Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC

Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the anti–PD-1 monoclonal antibody budigalimab in patients with relapsed or refractory small cell lung cancer (SCLC) (Abstract 8008). 

Lung Cancer

Tony S.K. Mok, MD, FRCPC, FASCO, on Advanced ALK-Positive NSCLC: 7-Year Update From the CROWN Trial

Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). At 5 years, median progression-free survival was not reached with lorlatinib in this population, representing the longest progression-free survival ever reported in advanced NSCLC (Abstract 8502). 

Gynecologic Cancers

Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease

Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.

Bladder Cancer

Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma

Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508). 

Breast Cancer

Walter Weber, MD, on Implant-Based Breast Reconstruction Techniques After Mastectomy

Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss or replacement of expander or implant—compared to subpectoral IBBR (Abstract 504). 

Advertisement

Advertisement




Advertisement